Clinical Trial Search

Primary: Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24 — 89.2; 53.8 percentage…

Primary: Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 — -71.97 percent change

Primary: Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26 — -4.79; -3.37; -3.09; -4.13 score on a scale — p=0.3202

Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants

Primary: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death — 504…

Primary: Frailty Scale Using Fried's Phenotype Method Based on Five Frailty Characteristics — 1.61; 0.94 score on a scale — p=0.01

Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events

Primary: Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE) — 92.0; 88.0 percentage of participants

Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58

Primary: Digoxin Cmax (Maximum Observed Plasma Concentration) — 2.315; 2.301 ng/mL

Primary: Bacterial Reduction — 4.04; 4.01; 1.60 log10 cfu/cm^2

Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants

Primary: Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria — 1; 1; 1; 2 Participants

Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 95.0 percentage of participants

Primary: Number of Participants With Clinically Significant AdV Infection — 3; 6; 6 Participants